RxDoctor Payments Data

Sarah Fedyk, MD

Internal Medicine · West Chester, OHNPI 1700176831

Payments from drug & device makers

$737in general payments, 2019–2025

Across 55 payments — averaging $13.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$496
  • Novo Nordisk$107
  • Pfizer$55
  • Merck$26
  • Abbott$22
  • Boston Scientific$18
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$737100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie42$496
Novo Nordisk5$107
Pfizer3$55
Merck2$26
Abbott1$22
Boston Scientific1$18
Lilly USA, LLC1$14

How this compares

$737 in reported general payments places this provider in the 70th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$47,906
Medicare patients
144
Services billed
638

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate41$65,160
MounjaroTirzepatide56$63,696
FarxigaDapagliflozin Propanediol44$49,520
OzempicSemaglutide44$44,005
JardianceEmpagliflozin20$27,914
EliquisApixaban25$26,308
TrulicityDulaglutide12$21,090
Lantus SolostarInsulin Glargine,hum.Rec.Anlog34$4,677
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate21$4,471
Atorvastatin Calcium389$2,850
Omeprazole236$2,756
Levothyroxine Sodium241$1,790
Desvenlafaxine Succinate ErDesvenlafaxine Succinate20$1,763
Celecoxib14$1,608
Rosuvastatin Calcium197$1,574

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$14$84,78568 claims
MerckJanuvia$26$65,16041 claims
Novo NordiskOzempic$107$44,00544 claims
PfizerEliquis$55$26,30825 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in West Chester

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →